What You Need to Know About Interferon Beta (Avonex®, Betaseron®, Extavia®, Rebif®)

Back in February, a study showed the variability of immune responses in different people with multiple sclerosis (MS) and suggested this heterogeneity affected responses to the commonly prescribed MS medication interferon-β, but blood biomarkers may exist that can help to determine those most likely to benefit from such treatment.

In this National MS Society video, watch Mark Skeen, MD, Associate Professor of Neurology at Duke University School of Medicine talk about Interferon Beta (Avonex®, Betaseron®, Extavia®, Rebif®).

Learn more about how MS patients’ likely response to Interferon-β may be evident in a blood biomarker.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

One comment

  1. Estimado Dr. Marcos Skeen:
    En año 2003 comienzo a recibir Avonex inyectable semanal me encontraba con 0 discapacidad.
    A 5 o 6 meses fui notando mejoría, se alejaron los hormigueos, compresión medular, cansancio, hacía una vida normal trabajando muchísimo.
    5 años con el mismo tratamiento me sentía cada vez mejor.
    Tuve una pausa sin medicamento de 13 meses, al comenzar de nuevo no pude tolerar Avonex…Copaxone…luego Betaferón 1b sentía que mi cuerpo andaba cada vez peor.
    Creo que mi cuerpo no era compatible con el Betaferón 1b, sentía que mi médula se quemaba, tratamiento durante 14 meses y abandono RMN mostró mas lesiones.
    Gracias por informar.

Leave a Comment

Your email address will not be published. Required fields are marked *